The significance of the co-existence of osteopontin and tumor-associated macrophages in gastric cancer progression

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Lin, Chang Ni ^a   Wang, Chih Jung ^a,b   Chao, Ying Jui ^a,b   Lai, Ming Derg ^a   Shan, Yan Shen ^a,b  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Biomarker; Cancer immunology; Gastric cancer; Osteopontin; Tumor associated macrophage

Indexed keywords

CD204 ANTIGEN; OSTEOPONTIN; TUMOR MARKER; UNCLASSIFIED DRUG; MSR1 PROTEIN, HUMAN; SCAVENGER RECEPTOR A;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; COCULTURE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; OVERALL SURVIVAL; PARACRINE SIGNALING; PROTEIN EXPRESSION; PROTEIN FUNCTION; STOMACH CANCER; SURVIVAL RATE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR VOLUME; U937 CELL LINE; UPREGULATION; AGED; ANIMAL; CELL TRANSFORMATION; DISEASE COURSE; GENE EXPRESSION; GENETICS; MACROPHAGE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; STOMACH NEOPLASMS;

ADULT; AGED; ANIMALS; BIOMARKERS, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MACROPHAGES; MALE; MICE; MIDDLE AGED; NEOPLASM STAGING; OSTEOPONTIN; PARACRINE COMMUNICATION; PROGNOSIS; SCAVENGER RECEPTORS, CLASS A; STOMACH NEOPLASMS; TUMOR BURDEN;

EID: 84926373271     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1114-3     Document Type: Article

References (38)

1. Orditura M, Galizia G, Sforza V, Gambardella V, Fabozzi A, Laterza MM, et al. Treatment of gastric cancer. World J Gastroenterol. 2014;20:1635-49.
2. Kwon HC, Kim SH, Oh SY, Lee S, Lee JH, Jang JS, et al. Clinicopathologic significance of expression of nuclear factor-kappaB RelA and its target gene products in gastric cancer patients. World J Gastroenterol. 2012;18:4744-50.
3. Nashimoto A, Akazawa K, Isobe Y, Miyashiro I, Katai H, Kodera Y, et al. Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry. Gastric Cancer. 2013;16:1-27.
4. Schwarz RE, Zagala-Nevarez K. Recurrence patterns after radical gastrectomy for gastric cancer: prognostic factors and implications for postoperative adjuvant therapy. Ann Surg Oncol. 2002;9:394-400.
5. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006;24:2903-9.
6. Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol. 2004;22:2395-403.
7. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860-7.
8. Gilmour J. Clinical Aspects of Carcinoma of Stomach in Diagnosis - Based Upon the Study of 146 Cases. Br Med J. 1958;1:745-8.
9. Gilmour J. The Surgical Aspects of Gastritis and Its Role in Gastric Pathology. Br J Surg. 1961;49:278-88.
10. Correa P. Clinical Implications of Recent Developments in Gastric-Cancer Pathology and Epidemiology. Semin Oncol. 1985;12:2-10.
11. Ohno S, Inagawa H, Dhar DK, Fujii T, Ueda S, Trchibana M, et al. The degree of macrophage infiltration into the cancer cell nest is a significant predictor of survival in gastric cancer patients. Anticancer Res. 2003;23:5015-22.
12. Qian BZ, Pollard JW. Macrophage Diversity Enhances Tumor Progression and Metastasis. Cell. 2010;141:39-51.
13. Ohta M, Kitadai Y, Tanaka S, Yoshihara M, Yasui W, Mukaida N, et al. Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human gastric carcinomas. Int J Oncol. 2003;22:773-8.
14. Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Okumura H, Matsumoto M, et al. Tumor-associated macrophage (TAM) infiltration in gastric cancer. Anticancer Res. 2003;23:4079-83.
15. Rudland PS, Platt-Higgins A, El-Tanani M, De Silva Rudland S, Barraclough R, Winstanley JH, et al. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res. 2002;62:3417-27.
16. Hu Z, Lin D, Yuan J, Xiao T, Zhang H, Sun W, et al. Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer. Clin Cancer Res. 2005;11:4646-52.
17. Pan HW, Ou YH, Peng SY, Liu SH, Lai PL, Lee PH, et al. Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer. 2003;98:119-27.
18. Wu CY, Wu MS, Chiang EP, Wu CC, Chen YJ, Chen CJ, et al. Elevated plasma osteopontin associated with gastric cancer development, invasion and survival. Gut. 2007;56:782-9.
19. Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, et al. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst. 2002;94:513-21.
20. Sakaguchi H, Fujimoto J, Hong BL, Tamaya T. Clinical implications of osteopontin in metastatic lesions of uterine cervical cancers. Cancer Lett. 2007;247:98-102.
21. Wang ZM, Cui YH, Li W, Chen YS, Liu TS. Lentiviral-mediated siRNA targeted against osteopontin suppresses the growth and metastasis of gastric cancer cells. Oncol Rep. 2011;25:997-1003.
22. Liu J, Liu Q, Wan Y, Zhao Z, Yu H, Luo H, et al. Osteopontin promotes the progression of gastric cancer through the NF-kappaB pathway regulated by the MAPK and PI3K. Int J Oncol. 2014;45:282-90.
23. Kurahara H, Shinchi H, Mataki Y, Maemura K, Noma H, Kubo F, et al. Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. J Surg Res. 2011;167:e211-9.
24. Mahmoud SM, Lee AH, Paish EC, Macmillan RD, Ellis IO, Green AR. Tumour-infiltrating macrophages and clinical outcome in breast cancer. J Clin Pathol. 2012;65:159-63.
25. Ryder M, Ghossein RA, Ricarte JCM, Knauf JA, Fagin JA. Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr Relat Cancer. 2008;15:1069-74.
26. Laoui D, Movahedi K, Van Overmeire E, Van den Bossche J, Schouppe E, Mommer C, et al. Tumor-associated macrophages in breast cancer: distinct subsets, distinct functions. Int J Dev Biol. 2011;55:861-7.
27. Mielgo A, Schmid MC. Impact of tumour associated macrophages in pancreatic cancer. BMB Rep. 2013;46:131-8.
28. Imano M, Satou T, Itoh T, Sakai K, Ishimaru E, Yasuda A, et al. Immunohistochemical expression of osteopontin in gastric cancer. J Gastrointest Surg. 2009;13:1577-82.
29. Zhu W, Guo L, Zhang B, Lou L, Lin Z, Zhu X, et al. Combination of osteopontin with peritumoral infiltrating macrophages is associated with poor prognosis of early-stage hepatocellular carcinoma after curative resection. Ann Surg Oncol. 2014;21:1304-13.
30. Kale S, Raja R, Thorat D, Soundararajan G, Patil TV, Kundu GC, et al. Osteopontin signaling upregulates cyclooxygenase-2 expression in tumor-associated macrophages leading to enhanced angiogenesis and melanoma growth via alpha9beta1 integrin. Oncogene. 2014;33:2295-306.
31. Giachelli CM, Lombardi D, Johnson RJ, Murry CE, Almeida M. Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo. Am J Pathol. 1998;152:353-8.
32. Zhou Y, Dai DL, Martinka M, Su M, Zhang Y, Campos EI, et al. Osteopontin expression correlates with melanoma invasion. J Invest Dermatol. 2005;124:1044-52.
33. Cheng J, Huo DH, Kuang DM, Yang J, Zheng L, Zhuang SM. Human macrophages promote the motility and invasiveness of osteopontin-knockdown tumor cells. Cancer Res. 2007;67:5141-7.
34. Song G, Ouyang G, Mao Y, Ming Y, Bao S, Hu T. Osteopontin promotes gastric cancer metastasis by augmenting cell survival and invasion through Akt-mediated HIF-1alpha up-regulation and MMP9 activation. J Cell Mol Med. 2009;13:1706-18.
35. Wai PY, Kuo PC. Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev. 2008;27:103-18.
36. Shevde LA, Samant RS, Paik JC, Metge BJ, Chambers AF, Casey G, et al. Osteopontin knockdown suppresses tumorigenicity of human metastatic breast carcinoma, MDA-MB-435. Clin Exp Metastasis. 2006;23:123-33.
37. Crawford HC, Matrisian LM, Liaw L. Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo. Cancer Res. 1998;58:5206-15.
38. Rittling SR, Chambers AF. Role of osteopontin in tumour progression. Br J Cancer. 2004;90:1877-81.